Edition:
India

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.03CAD
1:29am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.03
Open
$0.03
Day's High
$0.03
Day's Low
$0.03
Volume
2,937,180
Avg. Vol
3,415,942
52-wk High
$1.01
52-wk Low
$0.02

Latest Key Developments (Source: Significant Developments)

Prometic Reports Its 2019 First Quarter Financial Results
Thursday, 9 May 2019 

May 8 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS 2019 FIRST QUARTER FINANCIAL RESULTS.Q1 REVENUE C$8.2 MILLION VERSUS C$4.3 MILLION.PROMETIC LIFE SCIENCES - QTRLY NET LOSS OF $28.8 MILLION COMPARED TO A NET LOSS OF $34.6 MILLION FOR THE CORRESPONDING PERIOD OF 2018.  Full Article

Prometic Secures Additional $5 Mln Tranche From Structured Alpha Lp Under Its Existing Credit Facilities
Monday, 25 Mar 2019 

March 25 (Reuters) - Prometic Life Sciences Inc ::PROMETIC SECURES ADDITIONAL USD $5 MILLION (CAD $6.7 MILLION) TRANCHE FROM STRUCTURED ALPHA LP, AN AFFILIATE OF THOMVEST ASSET MANAGEMENT INC., UNDER ITS EXISTING CREDIT FACILITIES.PROMETIC LIFE SCIENCES INC - PROCEEDS OF THIS LOAN EXTENSION WILL BE USED TO SATISFY NEAR-TERM CASH REQUIREMENTS OF CORPORATION..  Full Article

Prometic Life Sciences Q4 Total Revenue $6.6 Mln Vs $4.1 Mln
Thursday, 29 Mar 2018 

March 28 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS Q4-2017 AND YE-2017 FINANCIAL RESULTS AND PROVIDES UPDATE ON ACTIVITIES.‍TOTAL REVENUES FOR Q4 ENDED DECEMBER 31, 2017 WERE $6.6 MILLION COMPARED TO $4.1 MILLION FOR Q4 ENDED DECEMBER 31, 2016​.PROMETIC LIFE SCIENCES - ‍RECEIVED FDA INVESTIGATIONAL NEW DRUG (IND) APPROVAL TO COMMENCE ITS PIVOTAL PHASE 3 CLINICAL TRIAL OF PBI-4050 DRUG ​.  Full Article

Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins
Monday, 5 Mar 2018 

March 5 (Reuters) - Prometic Life Sciences Inc ::PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS.PROMETIC LIFE SCIENCES INC - ‍COSTS ASSOCIATED WITH CLINICAL PROGRAM WILL NOT IMPACT FY2018​.  Full Article

Prometic Receives Rare Pediatric Disease Designation From U.S. FDA For Its Inter-Alpha-Inhibitor-Proteins
Monday, 5 Mar 2018 

March 5 (Reuters) - Prometic Life Sciences Inc ::PROMETIC RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM U.S. FDA FOR ITS INTER-ALPHA-INHIBITOR-PROTEINS.PROMETIC LIFE SCIENCES INC - IN ADDITION TO RARE PEDIATRIC DISEASE DESIGNATION, IAIP HAS ALSO BEEN GRANTED AN ORPHAN DRUG DESIGNATION BY FDA.PROMETIC LIFE SCIENCES - COSTS ASSOCIATED WITH CLINICAL PROGRAM RELATED TO THE PEDIATRIC & ORPHAN DRUG DESIGNATIONS "WILL NOT IMPACT OUR FY2018.  Full Article

Prometic Granted Orphan Drug Designation By FDA
Thursday, 15 Feb 2018 

Feb 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC GRANTED ORPHAN DRUG DESIGNATION BY FDA FOR INTER-ALPHA-INHIBITOR-PROTEINS FOR TREATMENT OF NECROTIZING ENTEROCOLITIS (NEC).PROMETIC LIFE SCIENCES INC - ORPHAN DRUG DESIGNATION STATUS HAS BEEN GRANTED TO ITS IAIP FOR TREATMENT OF NECROTIZING ENTEROCOLITIS BY U.S. FDA.  Full Article

Prometic's Pbi-4050 Phase 3 Pivotal Clinical Trial Design For Idiopathic Pulmonary Fibrosis Finalized
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Prometic Life Sciences Inc ::PROMETIC'S PBI-4050: PHASE 3 PIVOTAL CLINICAL TRIAL DESIGN FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) FINALIZED.PROMETIC LIFE SCIENCES - BASED ON RECOMMENDATIONS FROM FDA, CO NOW WILL UNDERTAKE AN "ALL COMERS STUDY".PROMETIC - PBI-4050 STUDY WILL ENROLL PATIENTS WITH MILD-TO-MODERATE IPF, REGARDLESS OF BACKGROUND STANDARD OF CARE WITH NINTEDANIB OR NOT.  Full Article

Prometic reports positive interim clinical data from IVIG phase 3 trial
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​.  Full Article

Prometic Q3 revenue C$24 million versus C$3.7 million
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Prometic Life Sciences Inc :Prometic reports 2017 third quarter highlights and financial results.Q3 revenue C$24 million versus C$3.7 million.Q3 revenue view c$6.9 million -- Thomson Reuters I/B/E/S.Prometic Life Sciences - ‍incurred a net loss of $17.8 million for quarter ended sept 30, compared to net loss of $28.0 million for quarter ended Sept 30, 2016​.  Full Article

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Prometic Life Sciences Inc ::Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation.Prometic Life Sciences Inc - ‍up to 33 adult patients are expected to be enrolled in clinical trial​.  Full Article